Development of a Combined Artificial Whole Blood Substitute for Treating Hemorrhage and Shock in Healthy Adults

What this Trial Is About

Researchers are developing a whole blood substitute to use when banked blood is not available or suitable. This study focuses on creating a balanced resuscitation fluid that combines artificial components mimicking oxygen carriers, plasma, and platelets to treat both shock and coagulopathy. The goal is to produce a product that can improve care in both civilian and military trauma settings, especially during the critical first hours after injury. The study tests combinations of artificial blood components that have been designed to overcome problems seen in past blood substitutes, such as poor oxygen delivery and harmful effects on blood vessel regulation. These components can be stored dry for long periods and then reconstituted. The study involves healthy adult volunteers who provide blood samples to compare the artificial blood analogs performance with fresh and stored whole blood. Participants will undergo observational study procedures including blood donation and analysis. Researchers will assess how well the artificial blood analog delivers oxygen compared to stored blood over four years. Various laboratory tests will measure physical and functional performance such as hemodynamics and hemostasis. The study is designed to optimize the artificial bloods compatibility and effectiveness while monitoring safety and performance over time.

Consortium for Optimized Integration of Bio-Artificial Blood Components for Adaptive Resuscitation Therapy